Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tofacitinib may inhibit CD8+ T cell infiltration in alopecia areata by affecting the linoleic acid metabolism-Mg2+ pathway in a sodium sulfide-induced mouse model, highlighting new insights for clinical diagnosis and treatment strategies.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

This study found that certain lncRNA gene polymorphisms in HOTAIR and MALAT1 are associated with increased susceptibility to systemic lupus erythematosus, potentially informing clinical applications.

This study reported that the topical treatment HDMHG0401-10 significantly improved hair density in men with androgenetic alopecia compared to placebo, although subjective hair growth ratings were not significantly different.

This study found that acellular dermal matrix scaffolds may facilitate full-thickness skin wound healing by promoting a pro-regenerative immune response through M2 macrophage polarization via the Lamtor1 pathway.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

This case report describes a patient with a NUDT15 minor variant who experienced severe myelosuppression due to azathioprine, emphasizing typical symptoms as clues to the adverse reaction.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that the ACE gene DD genotype and D allele are linked to an increased risk of hypertensive IHD complications, with dyslipidemia also identified as a significant risk factor for ischemic heart disease.

At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

This study found that AHCC significantly reduced alopecia caused by Ara-C in neonatal rats and improved liver function affected by 6-MP and MTX in mice.

This study explored the role of miRNA-211 in Cashmere goat color regulation and found that miRNA-211 downregulates the gene AP1S2, significantly affecting melanogenesis and melanin content in Cashmere goat skin.

The researchers reported that in a mouse model of alopecia areata, tofacitinib treatment influenced disease progression by modulating CD8⁺ T cell infiltration through the linoleic acid metabolism and magnesium ion pathway, offering insights into potential treatment approaches.

This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

This study found that P311 triggers transdifferentiation of epidermal stem cells into myofibroblast-like cells via TGFβ1/Smad signaling during wound healing.

This study found that radiofrequency microneedling significantly enhanced the absorption of topical triamcinolone acetonide, with insertion depth being more influential than RF energy levels.

This study suggests that the DORN1 receptor may play a role in eATP-induced changes in stomatal aperture in Arabidopsis thaliana, but not in the eADP signaling pathway.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

This study found that solid-state fermentation using probiotic lactic acid bacteria significantly enhanced the antioxidant properties and bioactive composition of Radix Angelica gigas compared to non-fermented herbs, suggesting a potential method for modernizing traditional herbal medicine.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

This study developed a spring-driven microneedle booster that improved early and cumulative delivery of minoxidil, accelerating hair regrowth compared to traditional roller methods in an androgenetic alopecia model.

This study indicates that porcine acellular dermal matrix may aid hair follicle regeneration in mice by enhancing the expression of SDF-1 and the Wnt3a/β-catenin signaling pathway.

This study found that MEGA PROTAC improved the prediction of ternary structures with higher maximum DockQ scores compared to the BOTCP method in 16 out of 22 test cases.

DACC-based dressings are more effective than silver-based ones for treating chronic wounds with antimicrobial resistance.

This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.